Technical Data
CDKN3 (Cyclin-dependent Kinase Inhibitor 3, CDK2-associated Dual-specificity Phosphatase, Cyclin-dependent Kinase Interactor 1, Cyclin-dependent Kinase-interacting Protein 2, Kinase-associated Phosphatase, CDI1, CIP2, KAP)
CDKN3 encodes a dual specificity protein phosphatase which has been identified as a cyclin-dependent kinase inhibitor and has been shown to interact with, and dephosphorylate human CDK2 kinase. CDKN3 has also been shown to associate with human CDK3 and CDC2. The protein has been reported to remove phosphate from tyrosine residues in model substrates in vitro; however, a mutant protein that bears a lesion in the putative active site cysteine has been shown to lose catalytic activity. In HeLa cells, CDKN3 has been demonstrated to be expressed at the G1 to S transition and overexpression of wild-type CDKN3 has been shown to delay progression through the cell cycle. This gene has been reported to be deleted, mutated, or overexpressed in several kinds of cancers, including breast and prostate cancers.

Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 2-4ug/ml
Immunohistochemistry (Formalin fixed paraffin embedded): 5ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
50ug-20CBlue IceHumanRabbit
Synthetic peptide corresponding to aa195-212 from human CDKN3 (KLH).
Purified by immunoaffinity chromatography.
Supplied as a liquid.
Recognizes human CDKN3.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.